Pax Neuroscience is focused on the commercialization of biomarker-based clinical laboratory services and products that target clinical depression and other mood disorders due to the serious unmet needs that are well documented, expensive and growing.

Slide 1

Today, the diagnosis of clinical depression is based on a patient’s self-report of symptoms and limited patient observation. Treatment is based on ‘trial and error’.

SLIDE 2

A major obstacle to the diagnosis, treatment and research on depression and depression therapeutics is the lack of a biological marker.

SLIDE 3

The Pax solution is a biomarker-based blood test that provides unbiased evidence of depression and treatment-response based on the biology of depression and mechanism of action of antidepressants.

SLIDE 4

Our breakthrough technology can revolutionize the diagnosis and therapy for a disease that afflicts ~20% of the U.S. population and about 15% of the populations of developed countries.

SLIDE 5

Our products and services will improve the standard of care and quality of life for patients with depression, and help return people to active, productive lives.

SLIDE 6